Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Joseph

Showing results (441-450 of 531) with videos related to

Pageof 54
Sort By:
MMWR. Morbidity and Mortality Weekly Report|September 27, 2019
Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015Emily C Somers, Jiha Lee, Afton L Hassett, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph, Christine A Pratilas, Poulikos I Poulikakos, et al.
European Urology Focus|July 21, 2017
Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related DeathMansi Parasramka, Daniel J Serie, Yan W Asmann, et al.
Journal of Autoimmunity|October 26, 2017
CD4+CD28+KIR+CD11a<sup>hi</sup> T cells correlate with disease activity and are characterized by a pro-inflammatory epigenetic and transcriptional profile in lupus patientsElizabeth Gensterblum, Paul Renauer, Patrick Coit, et al.
Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.
Journal of Clinical Pharmacology|October 15, 2013
Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patientsHong Sun, Catherine MacLeod, Kate Mostoller, et al.
International Journal of Molecular Sciences|December 24, 2021
Nicotinamide Mononucleotide Prevents Free Fatty Acid-Induced Reduction in Glucose Tolerance by Decreasing Insulin ClearanceAshraf Nahle, Yemisi Deborah Joseph, Sandra Pereira, et al.
Annals of Internal Medicine|April 20, 2005
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel, Grace H Lo, Janet T Holbrook, et al.
The Journal of Rheumatology|April 21, 2007
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian, Alfred D Mahr, Sohail S Ahmed, et al.
Pageof 54

Showing results (441-450 of 531) with videos related to

Sort By:
Pageof 54
MMWR. Morbidity and Mortality Weekly Report|September 27, 2019
Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015Emily C Somers, Jiha Lee, Afton L Hassett, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph, Christine A Pratilas, Poulikos I Poulikakos, et al.
European Urology Focus|July 21, 2017
Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related DeathMansi Parasramka, Daniel J Serie, Yan W Asmann, et al.
Journal of Autoimmunity|October 26, 2017
CD4+CD28+KIR+CD11a<sup>hi</sup> T cells correlate with disease activity and are characterized by a pro-inflammatory epigenetic and transcriptional profile in lupus patientsElizabeth Gensterblum, Paul Renauer, Patrick Coit, et al.
Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.
Journal of Clinical Pharmacology|October 15, 2013
Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patientsHong Sun, Catherine MacLeod, Kate Mostoller, et al.
International Journal of Molecular Sciences|December 24, 2021
Nicotinamide Mononucleotide Prevents Free Fatty Acid-Induced Reduction in Glucose Tolerance by Decreasing Insulin ClearanceAshraf Nahle, Yemisi Deborah Joseph, Sandra Pereira, et al.
Annals of Internal Medicine|April 20, 2005
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel, Grace H Lo, Janet T Holbrook, et al.
The Journal of Rheumatology|April 21, 2007
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian, Alfred D Mahr, Sohail S Ahmed, et al.
Pageof 54